dr. sledge on impact of cdk 4/6 agents in breast cancer
Published 7 years ago • 145 plays • Length 1:46Download video MP4
Download video MP3
Similar videos
-
2:40
dr. sledge on using tumor heterogeneity to guide treatment in breast cancer
-
1:37
dr. han on the differences between cdk 4/6 inhibitors in er breast cancer
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
5:47
monarche and pallas: a tale of two cdk4/6 inhibitors | george sledge jr
-
2:27
dr. o’shaughnessy on differentiating between cdk 4/6 inhibitors
-
2:25
dr. sledge discusses lasting issues in breast cancer
-
4:52
future directions: cdk4/6 inhibitors in breast cancer
-
3:21
benefits and challenges of cdk4/6 inhibitors
-
1:20
dr. finn on new cdk 4/6 inhibitors for breast cancer
-
1:01
dr. richardson on the use of cdk4/6 inhibitors in hr /her2- breast cancer
-
8:28
cdk4/6 inhibition in breast cancer
-
4:01
cdk4/6 inhibitors in breast cancer: ongoing research
-
2:07
dr ma on questions regarding treatment sequencing in cdk4/6 inhibitor–resistant breast cancer
-
3:27
metastatic breast cancer: cdk4/6 inhibitors
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
1:41
dr. harold j. burstein on cdk4/cdk6 inhibitor abemaciclib in breast cancer
-
1:31
dr. sledge on using pcr to determine therapy benefit for breast cancer
-
4:15
hr breast cancer: factors in selecting a cdk4/6 inhibitor
-
5:43
cdk 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer